These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31128259)

  • 1. Towards the automated economic assessment of newborn screening for rare diseases.
    Prieto-González D; Castilla-Rodríguez I; González E; Couce ML
    J Biomed Inform; 2019 Jul; 95():103216. PubMed ID: 31128259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated generation of decision-tree models for the economic assessment of interventions for rare diseases using the RaDiOS ontology.
    Prieto-González D; Castilla-Rodríguez I; González E; Couce ML
    J Biomed Inform; 2020 Oct; 110():103563. PubMed ID: 32931923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Methods and Newborn Screening Assessment.
    Castilla-Rodríguez I; Vallejo-Torres L; Couce ML; Valcárcel-Nazco C; Mar J; Serrano-Aguilar P
    Adv Exp Med Biol; 2017; 1031():267-281. PubMed ID: 29214578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
    Grosse SD; Thompson JD; Ding Y; Glass M
    Milbank Q; 2016 Jun; 94(2):366-91. PubMed ID: 27265561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dangerous and expensive screening and treatment for rare childhood diseases: the case of Krabbe disease.
    Lantos JD
    Dev Disabil Res Rev; 2011; 17(1):15-8. PubMed ID: 22447750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-effectiveness methods of newborn screening assessment.].
    Valcárcel Nazco C; García Pérez L; Linertová R; Castilla I; Vallejo Torres L; Ramos Goñi JM; Labrador Cañadas V; Couce ML; Espada Sáenz-Torres M; Dulín Íñiguez E; Posada M; Imaz Iglesia I; Serrano Aguilar P
    Rev Esp Salud Publica; 2021 Jan; 95():. PubMed ID: 33496278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the benefits, harms and costs of genomic newborn screening for rare diseases.
    Baple EL; Scott RH; Banka S; Buchanan J; Fish L; Wynn S; Wilkinson D; Ellard S; MacArthur DG; Stark Z
    Nat Med; 2024 Jul; 30(7):1823-1825. PubMed ID: 38898121
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rare diseases, definitions and epidemiology].
    Donnart A; Viollet V; Roinet-Tournay M
    Soins Pediatr Pueric; 2013; (274):14-6. PubMed ID: 24228328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
    Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
    Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging Evidence-Based Public Policy and Advocacy to Advance Newborn Screening in California.
    Bronstein MG; Pan RJ; Dant M; Lubin B
    Pediatrics; 2019 Feb; 143(2):. PubMed ID: 30606745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis.
    Knowles R; Griebsch I; Dezateux C; Brown J; Bull C; Wren C
    Health Technol Assess; 2005 Nov; 9(44):1-152, iii-iv. PubMed ID: 16297355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
    Pandor A; Eastham J; Beverley C; Chilcott J; Paisley S
    Health Technol Assess; 2004 Mar; 8(12):iii, 1-121. PubMed ID: 14982654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
    Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
    J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded newborn screening: social and ethical issues.
    Dhondt JL
    J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S211-7. PubMed ID: 20544288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newborn screening for inborn errors of metabolism: a systematic review.
    Seymour CA; Thomason MJ; Chalmers RA; Addison GM; Bain MD; Cockburn F; Littlejohns P; Lord J; Wilcox AH
    Health Technol Assess; 1997; 1(11):i-iv, 1-95. PubMed ID: 9483156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projected cost-effectiveness of statewide universal newborn hearing screening.
    Keren R; Helfand M; Homer C; McPhillips H; Lieu TA
    Pediatrics; 2002 Nov; 110(5):855-64. PubMed ID: 12415021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linking rare and common disease: mapping clinical disease-phenotypes to ontologies in therapeutic target validation.
    Sarntivijai S; Vasant D; Jupp S; Saunders G; Bento AP; Gonzalez D; Betts J; Hasan S; Koscielny G; Dunham I; Parkinson H; Malone J
    J Biomed Semantics; 2016; 7():8. PubMed ID: 27011785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ontological foundation for ocular phenotypes and rare eye diseases.
    Sergouniotis PI; Maxime E; Leroux D; Olry A; Thompson R; Rath A; Robinson PN; Dollfus H;
    Orphanet J Rare Dis; 2019 Jan; 14(1):8. PubMed ID: 30626441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
    Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
    Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economics of screening infants at risk of hearing impairment: an international analysis.
    Burke MJ; Shenton RC; Taylor MJ
    Int J Pediatr Otorhinolaryngol; 2012 Feb; 76(2):212-8. PubMed ID: 22129917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.